journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology

journal
https://www.readbyqxmd.com/read/28730742/microenvironment-modulation-and-enhancement-of-antilymphoma-therapy-by-the-heparanase-inhibitor-roneparstat
#1
LETTER
Anna Rossini, Franco Zunino, Giusi Ruggiero, Michelandrea De Cesare, Denis Cominetti, Monica Tortoreto, Cinzia Lanzi, Giuliana Cassinelli, Roberta Zappasodi, Claudio Tripodo, Alessandro Gulino, Nadia Zaffaroni, Massimo Di Nicola
No abstract text is available yet for this article.
July 21, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28707346/relationship-between-response-rates-and-median-progression-free-survival-in-non-hodgkin-s-lymphoma-a-meta-analysis-of-published-clinical-trials
#2
Naveen Mangal, Ahmed Hamed Salem, Mengyao Li, Rajeev Menon, Kevin J Freise
Demonstration of clinical effectiveness of a non-Hodgkin's lymphoma (NHL) treatment generally involves determination of progression-free survival (PFS). However, the long evaluation time of PFS limits its utility to make timely decisions in drug development. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in NHL. A database was systematically developed from 513 identified NHL trials reported from 1996 to 2015. Potential predictors of the relationship between response rates and PFS were evaluated, including age, sex, treatment, percentage of treatment-naïve patients, and subtype of NHL...
July 14, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28707331/epstein-barr-virus-lytic-cycle-involvement-in-diffuse-large-b-cell-lymphoma
#3
Melina Cohen, Aldana Georgina Vistarop, Fuad Huaman, Marina Narbaitz, Fernanda Metrebian, Elena De Matteo, María Victoria Preciado, Paola Andrea Chabay
Epstein-Barr virus (EBV)-mediated B cell transformation is achieved predominantly through the action of latent proteins, but recent evidence suggests that lytic EBV replication has also a certain pathogenic role in lymphomagenesis, at least in the early phases of cell transformation. Particularly, in diffuse large B cell lymphoma (DLBCL), the EBV lytic cycle is by and large unexplored, so to disclose lytic cell contribution to lymphomagenesis, our aim was to evaluate viral early and late lytic gene expression in relation to several immune response markers in a series of EBV+ DLBCL from Argentina...
July 14, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28707314/nodular-lymphocyte-predominant-hodgkin-s-lymphoma-in-daily-practice-a-multicenter-experience
#4
Aliihsan Gemici, Ismet Aydogdu, Hatice Terzi, Mehmet Sencan, Alma Aslan, Ali Hakan Kaya, Mehmet Sinan Dal, Meltem Olga Akay, Mehmet Hilmi Dogu, Orhan Ayyildiz, Fahri Sahin, Gulsum Akgun Cagliyan, Mehmet Yilmaz, Zafer Gokgoz, Yusuf Bilen, Cengiz Demir, Omur Gokmen Sevindik, Serdal Korkmaz, Bulent Eser, Fevzi Altuntas
Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37...
July 14, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28695659/epstein-barr-virus-negative-extranodal-true-natural-killer-cell-lymphoma-harbouring-a-kdm6a-mutation
#5
Naoko Tsuyama, Reimi Asaka, Akito Dobashi, Satoko Baba, Yuko Mishima, Kyoko Ueda, Masahiko Oguchi, Hideki Tsuji, Kiyohiko Hatake, Kengo Takeuchi
Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is an extranodal aggressive T or NK-cell lymphoma that is characteristically associated with Epstein-Barr virus (EBV) infection and cytotoxic tissue-destructive features. Although ENKTL is described as a distinct entity according to the 2008 WHO classification, a considerable complexity is associated with the differential diagnosis of other T-cell lymphomas with respect to tumour cell origins, locations, and the presence of EBV infection, as well as molecular and cytogenetic abnormalities...
July 10, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28695630/a-pilot-phase-ii-study-of-ofatumumab-monotherapy-for-extranodal-marginal-zone-b-cell-lymphoma-of-the-mucosa-associated-lymphoid-tissue-malt-lymphoma
#6
Barbara Kiesewetter, Ortrun Neuper, Marius E Mayerhoefer, Werner Dolak, Julius Lukas, Ingrid Simonitsch-Klupp, Markus Raderer
These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg) followed by 4 doses at 2-month intervals starting at week 8. According to protocol, a total of 16 patients were recruited (median age 69 years; range 38-85). Thirty one percent (5/16) of patients had primary gastric MALT lymphoma while the remaining 69% (11/16) presented with extragastric manifestations...
July 10, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28685863/efficacy-and-tolerability-of-the-histone-deacetylase-inhibitor-panobinostat-in-clinical-practice
#7
Marc-Andrea Baertsch, Jens Hillengass, Joanna Blocka, Stefan Schönland, Ute Hegenbart, Hartmut Goldschmidt, Marc S Raab
The histone deacetylase inhibitor panobinostat has shown efficacy in phase-II and phase-III trials for multiple myeloma and has recently received market approval in combination with bortezomib and dexamethasone. Here, we retrospectively report our single center experience with panobinostat/bortezomib/dexamethasone (FVD) in a heavily pretreated patient population (n = 24) with a high degree of refractoriness to proteasome inhibitors (PI) and immunomodulatory drugs (IMiD). Median age was 67 years (range 49-87) and the median number of prior therapies was 5 (range 2-17)...
July 7, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28685846/description-of-late-onset-neutropenia-in-indolent-lymphoma-patients-treated-with-bendamustine-plus-rituximab
#8
B Verriere, L Gastaud, E Chamorey, F Peyrade, E Deletie, K Bouredji, D Quinsat, R Schiappa, A Thyss, D Re
Bendamustine (B) associated with rituximab (R) is widely described in literature for the management of patients with chronic lymphoid leukaemia (CLL) and indolent non-Hodgkin lymphoma. Safety data regarding late hematotoxicity such as late onset neutropenia (LON) are scarce. The aim of our study was to assess the incidence and to identify risk factors for LON in patients with indolent non-Hodgkin lymphoma and CLL treated with B and R (B-R). One hundred forty five patients were treated with B-R as first or second line...
July 7, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28681549/ibrutinib-induced-rapid-response-in-chemotherapy-refractory-richter-s-syndrome
#9
LETTER
Angela Fischer, Sara Bastian, Sergio Cogliatti, Ulrich Mey, Jenny Saub, Urs Schanz, Barbara Padberg, Karin Hohloch
No abstract text is available yet for this article.
July 6, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28681529/targeting-complete-response-with-upfront-bortezomib-consolidation-versus-observation-after-the-achievement-of-complete-response-following-autologous-transplantation-for-multiple-myeloma-tuba-study
#10
Hideki Nakasone, Kiriko Terasako-Saito, Teiichi Hirano, Atsushi Wake, Seiichi Shimizu, Naoki Kurita, Etsuko Yamazaki, Kensuke Usuki, Kohei Akazawa, Junya Kanda, Koichiro Minauchi, Go Yamamoto, Shiori Tanimoto, Masaharu Kamoshita, Yasuhisa Yokoyama, Etsuo Miyaoka, Shuichi Ota, Shinichi Kako, Koji Izutsu, Yoshinobu Kanda
Complete response (CR) after treatment for multiple myeloma is associated with superior progression-free survival (PFS). Multiple myeloma patients were prospectively recruited for induction treatment with bortezomib and dexamethasone (BD) followed by autologous hematopoietic cell transplantation (auto-HCT) between 2010 and 2012. If patients did not achieve CR after auto-HCT, BD consolidation therapy was added to target CR. After the BD induction phase (n = 46), greater than or equal to CR was achieved in 4 patients (8%)...
July 6, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28681440/smoking-and-subsequent-risk-of-acute-myeloid-leukaemia-a-pooled-analysis-of-9-cohort-studies-in-japan
#11
Tomotaka Ugai, Keitaro Matsuo, Isao Oze, Hidemi Ito, Kenji Wakai, Keiko Wada, Chisato Nagata, Tomio Nakayama, Rong Liu, Yuri Kitamura, Akiko Tamakoshi, Ichiro Tsuji, Yumi Sugawara, Norie Sawada, Atsuko Sadakane, Keitaro Tanaka, Tetsuya Mizoue, Manami Inoue, Shoichiro Tsugane, Taichi Shimazu
Smoking has been identified as a significant risk factor for acute myeloid leukaemia (AML). However, epidemiological evidence for the effect of smoking on the risk of AML among Asians is scarce. Here, we investigated the impact of smoking habits on the risk of AML by conducting a pooled analysis of 9 population-based prospective cohort studies in Japan. We analysed original data on smoking habits at baseline from 9 cohort studies. Hazard ratios (HRs) in the individual studies were calculated using a Cox proportional hazard model adjusted for potential confounders and combined using a random-effects model...
July 6, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28665006/partial-deletion-of-the-alk-gene-in-alk-positive-anaplastic-large-cell-lymphoma
#12
Suguru Fukuhara, Junko Nomoto, Sung-Won Kim, Hirokazu Taniguchi, Akiko Miyagi Maeshima, Kensei Tobinai, Yukio Kobayashi
Anaplastic lymphoma kinase (ALK) protein is an orphan receptor tyrosine kinase that is constitutively activated by aberrant translocations of the ALK gene in anaplastic large cell lymphoma, ALK-positive and several other cancers. Additionally, aberrant mutation and amplification of the ALK gene, resulting in ALK kinase activation, were detected mainly in neuroblastoma. Recently, truncated ALK protein was also reported in neuroblastoma. Here, we describe a novel truncated form of the ALK transcript with in-frame skipping through exons 2 to 17 (ALKΔ2-17) in anaplastic large cell lymphoma, ALK-positive...
June 30, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28664979/intensive-induction-chemotherapy-vs-hypomethylating-agent-based-regimen-in-patients-aged-%C3%A2-70%C3%A2-years-with-newly-diagnosed-acute-myeloid-leukemia
#13
LETTER
Matthew J Lim, Aya Agha, Annie Im, Anastasios Raptis, Jing Z Hou, Michael Boyiadzis, Alison R Sehgal, Robert L Redner, Kathleen Dorritie, Stanley S Marks, Mounzer E Agha, Seah H Lim
No abstract text is available yet for this article.
June 30, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28660653/cytomegalovirus-infection-in-hematologic-malignancy-settings-other-than-the-allogeneic-transplant
#14
REVIEW
F Marchesi, F Pimpinelli, F Ensoli, A Mengarelli
Cytomegalovirus (CMV) infection in clinical settings other than the allogeneic transplant represents a poorly explored issue. Thus, we performed a comprehensive review of the medical literature about CMV infection in patients undergoing autologous hematopoietic stem cell transplant and in other nontransplant-related hematologic patients. In autologous hematopoietic stem cell transplant, a CMV reactivation is reported to occur in up to 41% of CMV seropositive patients, when a prospective monitoring of antigenemia and/or viremia by polymerase chain reaction was adopted...
June 29, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28643458/treatment-outcomes-for-hodgkin-lymphoma-first-report-from-the-brazilian-prospective-registry
#15
Irene Biasoli, Nelson Castro, Marcia Delamain, Talita Silveira, James Farley, Belinda Pinto Simões, Cristiana Solza, Monica Praxedes, Otávio Baiocchi, Rafael Gaiolla, Fernanda Franceschi, Caroline Bonamin Sola, Carla Boquimpani, Nelma Clementino, Guilherme Perini, Kátia Pagnano, Giovanna Steffenello, Jacques Tabacof, Gilberto de Freitas Colli, Andrea Soares, Carmino de Souza, Carlos Sérgio Chiattone, Cristiane Milito, José Carlos Morais, Nelson Spector
Data about Hodgkin lymphoma (HL) in developing countries are scarce and suggest the existence of substantial disparities in healthcare and outcomes in large areas of the world. In 2009, a prospective registry of HL was implemented in Brazil. Web-based data were contributed by 20 institutions across the country participating in the Brazilian Prospective Hodgkin's Lymphoma Registry. The aim of this study was to present the clinical features and outcomes of newly diagnosed patients with HL aged 13 to 90 years...
June 23, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28639416/persistently-low-lymphocyte-counts-after-fcr-therapy-for-chronic-lymphocytic-leukemia-are-associated-with-longer-overall-survival
#16
Erel Joffe, N Ariela Arad, Osnat Bairey, Riva Fineman, Rosa Ruchlemer, Naomi Rahimi-Levene, Lev Shvidel, Uri Greenbaum, Ariel Aviv, Tamar Tadmor, Andrei Braester, Neta Goldschmidt, Aaron Polliack, Yair Herishanu
Decreased absolute lymphocyte counts (ALCs) following frontline therapy for chronic lymphocytic leukemia may be associated with disease control, even in patients without evidence of minimal residual disease. We studied the prognostic significance of ALCs during the first year following treatment with fludarabine, cyclophosphamide, and rituximab (FCR). We evaluated 99 patients who achieved a partial response without lymphocytosis (<4.0 × 10(3) cells/μL) or better after FCR. Absolute lymphocyte counts were recorded at 3-, 6-, 9-, and 12-month posttreatment and correlated with overall survival (OS) and event-free survival (EFS)...
June 22, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28639256/response-and-survival-benefit-with-chemoimmunotherapy-in-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma
#17
Brady E Beltran, Pilar Quiñones, Domingo Morales, Jose M Malaga, Julio C Chavez, Eduardo M Sotomayor, Jorge J Castillo
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) is a haematologic malignancy with poor prognosis when treated with chemotherapy. We evaluated response and survival benefits of chemoimmunotherapy in EBV-positive DLBCL patients. A total of 117 DLBCL patients were included in our retrospective analysis; 33 were EBV-positive (17 treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP] and 16 with CHOP), and 84 were EBV-negative (all treated with R-CHOP)...
June 22, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28626947/pharmacokinetic-study-of-bortezomib-administered-intravenously-in-taiwanese-patients-with-multiple-myeloma
#18
Shang-Yi Huang, Cheng-Shyong Chang, Ta-Chih Liu, Po-Nan Wang, Su-Peng Yeh, Ching-Liang Ho, Ming-Chung Kuo, Hsuan-Yu Lin, Jan de Jong, Jia-Yi Chen, Ya-Wen Yang
This phase 4, single-arm, non-randomized, open-label, post approval commitment study evaluated the pharmacokinetics and safety of bortezomib in Taiwanese patients with multiple myeloma. Patients (≥20 years) with measurable secretory multiple myeloma (serum monoclonal IgG ≥10, IgA/IgE ≥5, IgD ≥0.5 g/L, IgM present [regardless of level], and urine M protein of ≥200 mg/24 h) received intravenous bortezomib 1.3 mg/m(2) , twice weekly for 2 weeks, followed by a 10-day resting phase (days 12 to 21)...
June 19, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28621491/outcome-of-patients-older-than-80%C3%A2-years-with-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-standard-immunochemotherapy-a-large-retrospective-study-from-4-institutions
#19
Stefania Gobba, Alden A Moccia, Wiebke Gulden-Sala, Annarita Conconi, Stefan Diem, Luciano Cascione, Gloria Iacoboni, Gloria Margiotta-Casaluci, Kathrin Aprile von Hohenstaufen, Anastasios Stathis, Felicitas Hitz, Graziella Pinotti, Gianluca Gaidano, Emanuele Zucca
Little information is available on the very elderly patients with diffuse large B-cell lymphoma (DLBCL). We performed a retrospective analysis of 281 patients >80 years old with newly diagnosed DLBCL treated in 4 referral institutions in Switzerland and Northern Italy. Primary end points were overall survival, progression-free survival, and cause-specific survival. Systemic chemotherapy was given to 239 patients, and 119 of them received rituximab in their initial treatment. At a median follow-up of 5.5 years, 5-year progression-free survival was 26% (95% confidence interval [CI], 20-32%), 5-year overall survival was 31% (95% CI, 25-37%), and 5-year cause-specific survival was 48% (95% CI, 41-55%) for the entire cohort...
June 16, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28580733/case-report-of-a-primary-effusion-lymphoma-successfully-treated-with-oral-valganciclovir-after-failing-chemotherapy
#20
Juan Marquet, Kyra Velazquez-Kennedy, Sandra López, Amparo Benito, María-Jesús Blanchard, Jose Antonio Garcia-Vela
Primary effusion lymphoma is a rare non-Hodgkin lymphoma that presents with pleural effusions and lacking of tumour mass. It is universally associated with human herpesvirus 8 (HHV8) and is more frequent among immunosuppressed patients. There is no standard treatment, chemotherapy and anti-HIV therapy have been used with poor results, but there is still no strong evidence supporting the use of valganciclovir. We present the case of a HIV positive man that presented with pleural effusion compatible with primary effusion lymphoma and positivity for HHV8 DNA in blood...
June 4, 2017: Hematological Oncology
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"